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Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia
of unknown cause. The most recent hypotheses on IPF pathogenesis suggest a central role of epithelial cell damage,
followed by a dysregulated molecular cross talk between epithelial cells and fibroblasts. Thus, IPF progression has
often been assimilated to that of cancer, and several signaling patterns appear to be disrupted in both diseases.
Here, we analyze the expression in an IPF series of a panel ofmolecules, which are known to play a role in tumorigenic
process. Our findings, although preliminary, reveal that IPF landscape is enriched in neoplastic potential expressed in a
context of complex genomic polyclonality and cellular heterogeneity. These results provide a rationale for further
investigations aimed to exploit—in a similar fashion to cancer—targeted therapies for a “precisionmedicine” approach
to IPF.
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Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease
of unknown etiology that is still lacking of effective therapy. IPF is
associated to lung cancer onset with a prevalence that is ranging from 4%
to 48% [1]. IPF progression has often been assimilated to that of a
neoplastic disease, and several signaling patterns appear to be disrupted in
both conditions [1]. For the past decades, comprehensive sequencing
programs have led to define cancer as, in essence, a genetic disease [2].
Cancer cells accumulate somatic DNA alterations that are responsible for
oncogene activation or tumor suppressor gene silencing. Among cancer
genes, the protein tyrosine kinase (TK) family plays a central role,
and several of these enzymes have been found to be altered in cancers
by a variety of molecular mechanisms. Kinases and their inhibitors,
phosphatases, are key regulators of several cellular functions, and their
appropriate activity is required for the cellular homeostasis; on the
contrary, their aberrant activation is crucial in driving oncogenesis.
The concept that cancer-mutated kinases molecularly mark “druggable”
targets has resulted in intensive efforts to survey the kinome across a wide
spectrum of human tumor types for mutations and to the development
of several targeted inhibitors [3].On this basis,we reasoned that, as inmalignant proliferations,TKactivation
could play a role in IPF, although few data about molecular mechanisms
involved in disease onset and progression are available. A confirmation
of a role of TK activation pathways in IPF would make them actionable
with specific molecules, in a similar fashion to cancer-targeted therapy.
Materials and Methods
We selected and analyzed 17 consecutive IPF samples derived from
medical thoracoscopy cases from a cohort of patients aged ≥18 years
who referred to our Institution for diagnosis and therapy. In all
patients with IPF, the histopathologic examination revealed all of the
major features of usual interstitial pneumonia (UIP ) [temporally and
Table 1. Clinical Characteristics of the Analyzed UIP and NSCLC Samples
ID
Patient
Gender Biopsy Age at
Diagnosis
(Years)
Histology Smoking Habit Mutational profile
EGFR KRAS
1 M Thoracoscopy 59 UIP Never smoker wt wt
2 M Thoracoscopy 54 UIP Past smoker L861Q wt
3 M Thoracoscopy 66 UIP Past smoker wt wt
4 M Thoracoscopy 51 UIP Current smoker wt wt
5 F Thoracoscopy 64 UIP Current smoker wt wt
6 F Thoracoscopy 58 UIP Current smoker wt wt
7 M Thoracoscopy 63 UIP Never smoker wt wt
8 M Thoracoscopy 62 UIP Current smoker wt wt
9 M Thoracoscopy 71 UIP Never smoker wt wt
10 M Thoracoscopy 48 UIP N.A. wt wt
11 M Thoracoscopy 60 UIP Never smoker wt wt
12 M Thoracoscopy 55 UIP N.A. wt wt
13 M Thoracoscopy 65 UIP Past smoker wt wt
14 M Thoracoscopy 64 UIP N.A. wt wt
15 M Thoracoscopy 80 UIP Past smoker L858R wt
16 M Thoracoscopy 77 UIP N.A. wt wt
17 M Thoracoscopy 63 UIP Past smoker wt wt
1 M Endobronchial 62 ADC Past smoker wt wt
2 F Transthoracic 70 ADC Past smoker L858R wt
3 M Endobronchial 65 ADC Past smoker wt wt
4 M Transbronchial 59 ADC Never smoker wt wt
5 F Transthoracic 67 ADC Never smoker del ex 19 wt
6 M Transthoracic 74 ADC Current smoker wt G12D
7 M Transthoracic 75 ADC Never smoker del ex 19 wt
8 F Transthoracic 66 ADC Past smoker G863D wt
9 F Endobronchial 58 ADC Past smoker wt wt
10 M Endobronchial 50 ADC Past smoker wt wt
11 M Tranthoracic 67 ADC Past smoker wt wt
12 M Tranthoracic 74 ADC Current smoker wt wt
13 F Tranthoracic 72 ADC Current smoker wt G13D
14 M Endobronchial 62 ADC Never smoker wt wt
15 F Endobronchial 79 ADC Never smoker wt wt
16 F Endobronchial 56 ADC Never smoker wt wt
17 M Endobronchial 64 ADC Current smoker wt G12D
18 M Endobronchial 73 ADC Past smoker wt wt
19 M Transthoracic 78 ADC Past smoker del ex 19 wt
20 F Transthoracic 68 ADC Past smoker wt wt
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(FF),microscopic honeycombing, subpleural and periseptal accentuation,
and absence of histologic features specific of other diseases], which is a
prerequisite for the diagnosis of IPF.The final diagnosis of IPFwas based
on the diagnostic criteria of the American Thoracic Society/European
Respiratory Society Consensus Classification System after evaluation of
all clinical, laboratory, and instrumental data [4,5]. We also checked 40
non–small cell lung cancer (NSCLC) samples [20 adenocarcinoma
(ADC) and 20 from squamous cell cancer] obtained through
endobronchial, transbronchial, or transthoracic biopsy. Clinical charac-
teristics of cases analyzed are reported in Table 1.
Immunohistochemical (IHC) analysis was performed with antibod-
ies against phospho–mammalian target of rapamycin (P-mTOR)
(1:100, rabbit monoclonal, clone 49 F9; Cell Signaling Technology,
Danvers,MA), phosphatase and tensin homolog (PTEN) (1:400,mouse
monoclonal, clone 6H2.1; Dako, Cernusco sul Naviglio, MI, Italy),
phospho-MET (P-met) (1:100, rabbit monoclonal, clone D26; Cell
Signaling Technology), and phospho-ezrin/radixin/moesin (P-ERM)
(1:300, rabbit monoclonal, clone 41A3; Cell Signaling Technology) on
4-μm–thick paraffin sections. Tissue sections were incubated at 60°C
overnight and then deparaffinized. The slides underwent 40 minutes
of heat-mediated antigen retrieval in citrate buffer (pH 6) and incubated
for 20 minutes with ready-to-use normal horse blocking serum.
Primary antibody was incubated overnight at +4°C. After inhibition of
endogenous peroxidase, the reactions were revealed with ImmPRESSAnti-Goat Ig detection system (Vector Laboratories, Burlingame, CA),
using DAB tetrahydrochloride as chromogen substrate (Dako). Finally,
all slides were counterstained with Harris hematoxylin to visualize the
nuclei. Each reaction set included a negative control obtained with
substitution of the primary antibody with dilution buffer and positive
controls as suggested by the manufacturer. Immunostained slides were
examined to identify the cell types expressing antigen and to
semiquantitatively score the amount of protein present in the lung.
For each case, genomic DNA was manually microdissected
from fibrotic areas highlighted on hematoxylin and eosin–stained sections
and processed for mutational analysis. Normal DNA was extracted from
healthy areas adjacent to fibrotic lesions and normal tissues from
lobectomies and used as control. The expression the mTOR and MET
kinases of the PTEN phosphatase and of ERM proteins was assessed
with IHC stains; the stained slides were reviewed by the study pathologist
(P.M.), and the results were classified as positive when strong
immunostain was observed and negative in absence of immunostain.
The presence of faint but specific (i.e., negative background) immunostain
was also recorded. Epidermal growth factor receptor (EGFR) and KRAS
mutational status was analyzed by real-time polymerase chain reaction
aspreviouslydescribed [6].Resultswereproperly compared to a seriesofNSCLC
samples (ADC) and squamous cell cancer as well as to normal lung tissue.
Results
Here, we report the results of a preliminary screening performed on a
series of IPF and lung cancer cases aimed at comparing the expression
of a panel of key molecules whose pathways are known to drive
NSCLC onset and progression [3]. In detail, we checked the status of
the EGFR and MET receptors together with that of the downstream
transducer KRAS and of intracytoplasmic signaling molecules as the
mTOR, the PTEN, and the ERM protein complex. Molecular
pathways in study are described in detail in Figure 1A.
Our preliminary data in IPF samples showed strong phospho-mTOR
immunoreactivity and scarce PTEN expression in activated type II
pneumocytes lining FF. Phospho-ERM was expressed on the luminal
and lateral cytoplasmic membranes of these cells. MET was expressed
in both epithelial and stromal cells, whereas PTEN was exclusively
expressed in myofibroblasts of FF. A similar immunoprofile in both
epithelial and stromal cells was demonstrated in cancers, whereas in
normal lungs, only m-TOR and PTEN were expressed at low levels
exclusively in bronchiolar epithelia. Immunophenotypes found are
illustrated in Figure 1B. We then moved to check the EGFR and KRAS
mutational profile of each analyzed sample. Two of the 15 analyzed
samples carried an EGFRmutation, in both cases affecting the exon 21.
The somatic origin of themutations found was confirmed by processing,
together with IPF DNA, normal matched DNA: mutations were found
only in IPF specimens, whereas adjacent normal areas showed wild-type
EGFR. No changes were documented in the hot-spot encoding region of
the KRAS gene. Results are summarized in Figure 1C.
Discussion
Although preliminary and limited, our findings allow drawing
some relevant considerations. Increased mRNA and protein levels
of EGFR have recently been described in patients with IPF [7].
Notably, we are reporting for the first time in IPF the presence
of activating mutations in the exon 21 of EGFR coding sequence,
which in NSCLC are known to be associated to sensitivity to targeted
inhibitors [3]. EGFR mutational incidence in IPF seems to be high
(13%), comparable to that occurring in NSCLC.
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Figure 1. Oncogenic activation in IPF. (A) The molecular oncogenic pathways analyzed. EGFR activation triggers the following two main
signaling pathways: KRAS-BRAF-MEK pathway, which, by activating ERK and the mitogen-activated protein kinase, sustains cell
proliferation; and PIK3CA-AKT-mTOR axis, which is mainly involved in cell survival and motility. Indeed, mTOR regulates cell growth by
controlling mRNA translation, ribosome biogenesis, autophagy, and metabolism. MET receptor is the key player of invasive growth
(or EMT), a physiological process that occurs during embryonic development and postnatal organ regeneration and that is usurped by
cancer cells. MET activation induces intramolecular phosphorylation of two tyrosine residues (Tyr1349 and Tyr1356); the latter creates
a unique docking site responsible for the recruitment of a large spectrum of downstream signal transducers, which ultimately activate
the invasive growth program (scattering, migration, proliferation, survival, and differentiation). It behaves as a sensor of adverse
microenvironmental conditions (hypoxia and radiation), drives cell invasion andmetastasis, and mediates adaptive resistance through the
transcriptional activation of a set of genes that control blood coagulation [1]. Phosphorylation of ERM leads to weakened self-association
and translocation to membrane-cytoskeleton interface. Active ERM interacts directly with actin and with several transmembrane- or
membrane-associated partners, thus contributing to tumor development and metastasis by causing cell depolarization, loss of contact-
dependent inhibition of proliferation, and increased motility and invasiveness. Activation of GTPase and RHOA leads to activation of ERM
through the activation of an effector kinase. (B) Comparative sections of oncogenic immunostaining in UIP and lung cancer (ADC).
Immunohistochemistry analysis of phosphorylated (P) oncomarkers expression in UIP compared to lung ADC. (C) Overall expression of
oncogenes and oncosuppressors. Schematic distribution of oncogenic activation in UIP compared to NSCLC and normal lung. *, apical
membrane; ^, nuclear and cytoplasmic; °, nuclear; when not otherwise specified, the immunostain was cytoplasmic. #, mutational
frequencies were comparable to already available data from COSMIC database (website at http://www.cancerrxgene.org).[1] Boccaccio
C, Comoglio PM (2006). Invasive growth: aMET-driven genetic programme for cancer and stem cells. BRAF; v-RAF murine sarcoma viral
oncogene homolog B1, MEK; also known asMAPKK, mitogen activated protein kinase (MAPK) kinase, ERK; extracellular signal-regalated
kinase, PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, Rhoa; Ras homolog gene family, member A,
COSMIC; Catalogue Of Somatic Mutations In Cancer. Nat Rev Cancer 6, 637–645.
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pathogenesis of lung cancer and IPF. Smoking is strongly associated
with IPF and is a strong negative predictive factor for tumors withEGFR mutations according to previous reports. The issue of EGFR
mutation incidence and smoking habit focuses on the following
two points: the frequency of mutation detection in smokers on one
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on the other. Cigarette smoking is the major cause of lung cancer
(about 75% of cases) that, in turn, is the leading cause of death in the
Western world [3]. Although early studies reported EGFR activating
mutations in ADC aroused in female patients with East Asian
ethnicity and never or light smokers [8], it is now known that
mutations can be also found in ADC specimens from men and people
who smoke cigarettes [9,10]. In IPF, the prevalence of tobacco use
ranges from 41% to 83% [11,12]; whereas no data are available,
to our knowledge, about EGFR mutational incidence in IPF. Within
the limits of the cohort analyzed in the present study, both the two
patients with mutated IPF were previous smokers (b30 pack-years),
but also patients with EGFR-mutated cancer had a history of cigarette
smoking (Table 1). The second point is that cigarette smoking dosage
of ≥30 pack-years has been reported to be an independent negative
predictive factor of EGFR–TK inhibitor (TKI) treatment outcome
in patients with lung ADC with activating EGFR mutations [10].
Potential explanation for this correlation has been related to the fact
that cigarette smoking not only activates EGFR but also stabilizes the
EGFR protein by preventing from ubiquitination and degradation,
remaining membrane bound or trafficked to perinuclear region.
Thus, exposure to cigarette smoke results in prolonged signaling by
the EGFR and may contribute to uncontrolled lung cell growth [13].
Moreover, preclinical investigation conducted by Filosto et al. also
suggested that cigarette smoking induces conformational change of
EGFR, resulting in downstream activation through c-Src and caveolin
1 binding [14]. We should only hypothesize that smoking could act
on mutated EGFR aroused in IPF in a similar fashion to that in
cancer, but experimental data are clearly required, and this point goes
beyond the scope of this paper.
EGFR mutation detection in IPF is unlikely to predict sensitivity
to specific agents. It should be underlined that, because real-time
polymerase chain reaction sensitivity enables the identification
of mutations in samples containing less than 30% mutated cells, which
can be otherwise missed by direct sequencing [15], we probably identified
an emerging clone of EGFR-mutated cells in a genetically heterogeneous
population, whose role in the progression of lung fibrosis or, possibly, in
oncogenesis needs further investigation. Indeed, due to the multiclonal
FF cellularity, the emergence of an oncogenic phenotype in IPF is
unlikely to be read in a context of “oncogenic addiction” [16], which is
considered the driving force of malignant proliferation.
Nevertheless, it should be underlined that a relation subsists
between NSCLC associated with ILD and EGFR mutations [17–19].
Indeed, it has been reported that EGFR mutation is rare in Asian
patients with ILD and lung cancer. In particular, an inverse
association has been reported between occurrence of ILD and tumors
with EGFR mutations in patients with lung ADC [19]. From this
perspective, the finding of EGFR-mutated cells in the fibrotic area
points out some relevant considerations. First of all, it is well
documented that treatment with EGFR TKIs gefitinib and erlotinib
is associated with a significant increase in the risk of developing both
all-grade and fatal ILD events in advanced EGFR-mutated NSCLC
[20]. In those settings, the occurrence of ILD is a secondary—
iatrogenic—event, although the bimolecular mechanisms of ILD
induction have not been yet clarified. A different question is that
associating ILD and lung cancer and two different links may be
identified. The first is that, within respect to IPF, growing evidence
suggests that this process is driven by pathogenic events very similar to
cancer, including epigenetic and genetic changes, altered response toregulatory signals, abnormal expression of microRNAs, and activation
of specific signaling pathways [1] IPF also resembles cancer with
regard to its poor response to medical treatment and prognosis.
The other is that ILD, and mainly IPF, most often coexists with cancer
as concomitant disease. In this scenario, ILD seems to be inversely
associated to the occurrence of EGFR mutation in lung cancer.
The EGFR is a member of the EGFR receptor family TKs that
represent both key regulators of normal cellular development and
critical players in a variety of pathophysiological phenomena, among
which is cancer [21]. In NSCLC, EGFR inappropriate activation
is mainly due to the occurrence of somatic mutations affecting the
sequence encoding for receptor TK domain. Mutation detection has
been found to be closely linked with favorable response to the anti-
EGFR TKIs gefitinib and erlotinib, according to the “oncogenic
shock” model [22].
Although very preliminary and performed on a limited cohort
of cases, our findings reported the occurrence of EGFR mutations
in IPF areas, with an incidence that seems not to be trivial. Notably,
the fibrotic EGFR-mutated samples analyzed here are not aroused
after an anti-EGFR therapy nor are associated to a synchronous
carcinogenic process. It is well known that, in normal airway, EGFR
expression is low and only transiently increased during repair [23].
The EGFR pathway has been implicated in lung fibrosis pathogenesis
through the activation of an EGFR-dependent paracrine loop
between epithelial and fibroblast cells, resulting in excessive collagen
production and deposition [24]. From this perspective, clonal
heterogeneity that characterizes FF—in contrast to monoclonality
that is a hallmark of cancer—brings into question the role of EGFR
activation by mutation in lung fibrogenetic process and if it could be
therapeutically exploited in a similar way of cancer-targeted therapies.
On the basis of the biologic functions of the receptor of EGF [25,26], we
could hypothesize that its activation is required in FF to induce cell
proliferation and also to prevent apoptosis in a context of cross talk
between pneumocytes and myofibroblasts. It is unlikely that fibroblasts
may rely (or “be addicted to”) on this sustained EGFR activity for growth
and proliferation. Nevertheless, there are no elements to exclude that the
EGFR-mutated cellular fraction could represent an early marker of
malignant transformation arousing inside the fibrotic landscape, because
mutation of the TK domain of EGFR is an early event in the
pathogenesis of lung ADCs [27]. Further experimental data are required
to validate our very preliminary findings and to clarify the many
questions that remain open on the role played by EGFR in fibrogenesis.
Quite unexpectedly in such a heterogeneous context, the analyzed
kinases seem to be distributed according to a spatial gradient,
throughout the cell layers of the FF [28]. Interestingly, a similar
profile of expression was observed at the interface between epithelial
neoplastic cells and tumor stroma in most NSCLCs. As discussed
above, it could be hypothesized that IPF fibroblasts may rely on TK
activation for their inappropriate proliferation and that the specific
TK phosphorylation could be a consequence rather than the cause of
the proliferating phenotype, or that fibroblast proliferation is driven
through abnormal signaling by epithelial cells, in a similar fashion
as that observed in stromal proliferation in epithelial tumors [29].
The mTOR is an intracellular serine/threonine protein kinase that has
been identified as a major link in the cellular processes that contribute
to the development and progression of cancer [30]. As in cancer, in
IPF, mTOR expression may directly impact the translational capacity
of the epithelial cells, thus sustaining their proliferation. As far as
ERM is concerned, it is active in organizing the cell cortex and in
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that is often disrupted in tumorigenesis [31]. Due to its function as
scaffold in supporting cell growth and promoting the proliferative
frontline, we hypothesized that ERM could potentially be implicated in
IPF proliferative processes. However, we did not document a significant
activation of phospho-ERM in cells of the FF or inNSCLC. The profile
of PTEN expression is more puzzling. We observed clear and strong
nuclear PTEN reactivity in FF mesenchymal cells. This finding is at
odds with reported data and with the knowledge on PTEN function:
its loss of function rather than overexpression has been associated with
cancer progression and pulmonary fibrosis through reduced apoptosis,
and previous studies reported the absence of IHC PTEN expression
in IPF myofibroblasts [32]. Given the complex mechanisms of PTEN
regulation, protein expression does not necessarily imply increased
activity; thus, this aspect also needs further clarification. Finally, we
demonstrated that both myofibroblasts and epithelial cells of FF harbor
MET, the TK receptor for scatter factor/hepatocyte growth factor
(HGF) [3] in its activated form. It has been suggested that low levels of
HGF in the fibrotic lung may contribute to the development of lung
fibrosis by inhibiting epithelial-to-mesenchymal transition (EMT) [33];
however, several evidences point toward a role of EMT in the formation
of FF in IPF [34]. We have now shown that the HGF receptor MET is
specifically and strongly expressed in FF cells, thus suggesting that,
besides the reported dysregulation of cadherins [35], the activation of
MET could have a role in the inappropriate activation of EMT in IPF.
Overall, these data reveal that IPF landscape is enriched in neoplastic
potential expressed in a context of complex genomic polyclonality and
cellular heterogeneity. Rather than being a drivingmechanism conferring
clonal growth advantage, TK activation may represent a tactic exploited
in IPF to promote continued and diffuse cell growth and proliferation.
On this perspective, pharmacological targeting of oncogenic molecules
in IPF may represent an approach to hamper progression rather than to
affect cell growth and survival (addiction).
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